ArticleAJNR. American journal of neuroradiology2025
Protective Factors of Postendovascular Therapy Restenosis for Symptomatic Intracranial Arterial Stenosis: A Retrospective Analysis.
Article in AJNR. American journal of neuroradiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
background and purposeSymptomatic intracranial arterial stenosis (ICAS) markedly increases the risk of recurrent ischemic stroke, with high restenosis rates after endovascular therapy. This study aims to identify factors influencing restenosis within 1 year after endovascular therapy for ICAS, with the goal of reducing restenosis rates through interventions targeting protective and risk factors. MATERIALS AND
methodsWe conducted a retrospective analysis of symptomatic patients with ICAS who underwent endovascular therapy between January 2016 and June 2023 at our hospital. Patients were divided into restenosis and nonrestenosis groups based on the occurrence of restenosis within 1 year after endovascular therapy. Data on clinical characteristics, type of endovascular therapy, postendovascular antiplatelet therapy, statin therapy, and risk factor management were collected and analyzed. Comparisons were made between groups regarding baseline characteristics, type of endovascular therapy (balloon angioplasty alone versus stent placement), and secondary prevention measures (dual antiplatelet therapy, optimal blood pressure, glucose, and lipid control, no current smoking). Binary logistic regression was used to determine independent protective and risk factors for restenosis.
resultsThe study included 154 participants, with 45 in the restenosis group (mean age 61.1 ± 9.8 years) and 109 in the nonrestenosis group (mean age 58.5 ± 11.3 years). There were no statistically differences in baseline characteristics between groups; however, the restenosis group had a lower proportion of stent placement than balloon angioplasty (42.2% versus 61.5%;
conclusionsStent placement, optimal glucose and lipid control, and no current smoking independently protect against postendovascular restenosis in patients with symptomatic ICAS. Effective management of these risk factors is crucial in clinical practice to minimize the incidence of postendovascular restenosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.